GPRC5D/CD3 BiTEs

DRUG3 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China

Conditions

Multiple Myeloma, Newly DiagnosedMultiple Myeloma, Plasma Cell Leukemia

Phase 2

MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma

RecruitingNCT07106736

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma, Newly Diagnosed

Start: 2025-08-10End: 2029-08-01Target: 60Updated: 2025-08-06

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

RecruitingNCT07106684

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma, Plasma Cell Leukemia

Start: 2025-08-10End: 2029-08-01Target: 20Updated: 2025-08-06

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma

RecruitingNCT07106710

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma, Newly Diagnosed

Start: 2025-08-10End: 2028-08-01Target: 30Updated: 2025-08-06